Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
NCT06071897
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Neuroblastoma
Ganglioneuroblastoma
Interventions
DRUG:
monoclonal antibodies GD2
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology